ClinicalTrials.gg
Status unknownNCT03709316Updated Jun 2, 2021

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

A Phase 3 interventional study of ZL-2306 (Nirapairb) and Placebo Comparator in Ovarian Cancer, sponsored by Zai Lab (Shanghai) Co., Ltd.. Status unknown at 31 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
5th of 44
384 · median 41
Started
2018
with 4 others
Phase 3
7 of 44
none open now
Registered
15th of 44
by date
Lead sponsor
4 of 44
Zai Lab (Shanghai) Co., Ltd.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 5th largest by enrollment, is one of 5 that started in 2018, is one of 7 in phase 3, and was the 15th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. The written form shall be signed before proceeding with any study-related procedure.
    1. The subject agrees to collection of blood samples for detection of gBRCA mutations (gBRCA mutation status must be known before randomization).
    1. The subject shall be a female, aged 18 years or older.
    1. confirmed high-grade serous/endometrioid or dominantly high-grade serous/endometrioid epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma (no histological restriction for patients carrying germline BRCA mutations).

Note: Patients who have received chemotherapy can also be enrolled if their tumors after chemotherapy cannot be pathologically graded.

    1. FIGO staging is Stage III or IV.
    1. Criteria for previous surgery (meeting any of these):

      • Inoperable Stage III or IV patients
      • Stage IV patients, regardless of postoperative residual lesion status
      • Stage III patients who have undergone primary tumor reductive surgery with postoperative residual lesion status of R1 (microscopic residual lesions) or R2 (macroscopic residual lesions)
      • Stage III or IV patients who have undergone intermittent tumor reductive surgery (patients who have used neoadjuvant therapy) regardless of postoperative residual lesion status
    1. Criteria for previous chemotherapy:

      • It is allowed to enroll patients who have received intraperitoneal chemotherapy
      • Patients have completed at least 6 cycles yet no more than 9 cycles of platinum-containing chemotherapy (preferably carboplatin, but cisplatin is also acceptable)
      • Patients undergoing intermittent tumor reductive surgery should respectively receive at least 2 cycles of platinum-containing chemotherapy preoperatively and postoperatively, and receive a total of at least 6 cycles yet no more than 9 cycles of chemotherapy (preferably carboplatin, but cisplatin is also acceptable) preoperatively and postoperatively
      • Patients are assessed by the investigator to have achieved complete response (CR) or partial response (PR) after first-line platinum-containing chemotherapy, and the efficacy assessment should be performed after the end of at least 3 cycles of chemotherapy
      • CA-125 level must be within the normal range after the end of chemotherapy or has decreased by more than 90% during the course of first-line chemotherapy and remains so for at least 7 days (the elevation of CA-125 prior to enrollment shall not exceed 15% compared with the CA-125 level after the end of chemotherapy)
      • Patients must be randomized within 12 weeks since Day 1 of the last cycle of chemotherapy 8. Patients must be able to submit formalin-fixed, paraffin-embedded tumor tissue samples.
    1. physical condition score of the patient shall be 0 or 1.
    1. Organ function is in good condition, including:

      • ≥1.5×109/L
      • count ≥100×109/L
      • ≥100 g/L
      • Serum creatinine is not more than 1.5 times the normal upper limit, or rate is not less than 60 mL/min (calculated with Cockcroft-Gault formula)
      • Total is not more than 1.5 times the normal upper limit, or direct bilirubin is not more than 1.0 time the normal upper limit.
      • and ALT are not more than 2.5 times their normal upper limit, and with existence of hepatic , these values must not be more than 5 times their normal upper limit.
    1. Only the female patient who has been tested with pregnancy-negative result and had made a commitment to adopt effective contraption measures or to avoid sexual behavior from the start to the completion of the study and within 3 months after the last administration of study medication is eligible to be enrolled into the study. Or female patients without may be enrolled in the study, defined as follows:

      • A female who has undergone surgical operation (e.g., hysterectomy, bilateral ovariectomy, or bilateral tubal resection); or
      • A female aged 60 years or older; or
      • A female, aged ≥40 years and \<60 years, with a period of menolipsis for 12 months or longer, whose follicle-stimulating hormone test results are within the reference range of the study institution.
    1. Patients must be able to take medication orally and have the ability to comply with the protocol.
    1. Any previous toxic and side effect of the patient has restored to grade ≤1 or the baseline level, except for CTCAE grade ≤2 symptomatically stable sensory neuropathy or alopecia.

Exclusion criteria

Exclusion Criteria:

    1. Patients diagnosed with mucinous, clear cell subtypes of epithelial ovarian cancer, carcinosarcoma, or undifferentiated ovarian cancer.
    1. Stage III patients who have undergone primary tumor reductive surgery with postoperative status of R0-complete resection (with no residual lesion).
    1. Patients who have undergone tumor reductive surgery more than twice.
    1. Patients who plan to or have used bevacizumab as maintenance therapy after platinum-containing chemotherapy. If the patient received bevacizumab in platinum-containing chemotherapy but did not receive bevacizumab as maintenance therapy, and the last dose of bevacizumab was used ≥ 28 days before signing the master form, the patient can be enrolled.
    1. Patients who are known to be allergic to active or inactive ingredients of ZL-2306 (niraparib) or other drugs with similar chemical structures to ZL-2306 (niraparib).
    1. Patients who have previously been treated with PARP inhibitors (including niraparib).
    1. Patients who have received other study drug treatment within 4 weeks prior to the first administration or \< 5 elimination half-lives of the study drug (whichever is longer).
    1. Patients with ≥ grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy for more than 4 weeks.
    1. Patients with transfusion-dependent anemia or thrombocytopenia, including:

      • Patients who have received blood transfusion ( or red blood cell) within 2 weeks before the first dose
      • Patients who have received colony stimulating factor therapy (e.g., granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), or recombinant erythropoietin) within 2 weeks before the first dose
    1. Patients who have undergone ascites drainage within 4 weeks prior to enrollment.
    1. or that have not been treated or whose symptoms have not been controlled (e.g., new or worsening symptoms or signs, or the required dose of hormones is not yet stable). Note: It is not necessary to perform an imaging scan to confirm whether there is a brain metastasis or not; patients with spinal cord compression who have received symptomatic treatment and have evidence on clinical stable status of the disease for at least 28 days could still be considered as eligible for enrollment.
    1. Patients who have received a major surgery 3 weeks before the start of the study, or is subject to any surgical effect that has not yet been recovered after surgery.
    1. Patients who have received palliative radiotherapy for > 20% of bone marrow 3 weeks prior to enrollment.
    1. Patients suffered from invasive cancers other than ovarian cancer within 5 years prior to enrollment (except for treated carcinoma in situ of cervix, non-melanoma and ductal carcinoma in situ).
    1. Patients who have been diagnosed previously or currently with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
    1. Patients who have got other severe or uncontrollable diseases, including but not limited to:

      • Hardly controllable nausea and vomiting, inability to swallow the study drug, and any gastrointestinal disease that may interfere with the absorption and metabolism of the drug
      • (HIV) infection, active hepatitis (, )
      • Uncontrolled ventricular arrhythmias, myocardial infarction that occurred within 3 months before enrollment
      • Uncontrollable grand mal epilepsy, unstable spinal cord compression, superior vena cava syndrome or other psychiatric disorders that may affect signing of the informed consent by the patient
      • Immunodeficiency (except for splenectomy), or other diseases which, as believed by investigators, could expose the patient to a high risk
    1. Patients who are pregnant or breastfeeding currently, or expect to plan for pregnancy in the course of the study treatment.
    1. The interval (QTc) is more than 470 msec; if the patient has an extended QTc interval, but investigators find such a extension is caused by a cardiac pacemaker (without any other cardiac abnormality), it shall be necessary to determine whether the patient is eligible for enrollment or not based on the discussion with the study physician from the sponsor.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    ZL-2306 (Nirapairb)

    The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

    Drug: ZL-2306 (Nirapairb)

  • Placebo comparator
    Placebo

    The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

    Drug: Placebo Comparator

Interventions

  • The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

  • DrugPlacebo Comparator

    The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

06

What researchers measure

Primary outcomes

  1. BICR-assessed progression-free survival (PFS)

    the time from randomization to progressive disease or death due to various causes assessed by the BICR according to RECIST 1.1, whichever occurs first

    Time frame: Approximately 36 months since the first subject enrolled

Secondary outcomes

  1. Overall survival (OS)

    the time from the date of randomization to the date of death caused by any reason.

    Time frame: Approximately 36 months since the first subject enrolled

  2. Time to first subsequent anti-tumor treatment (TFST)

    the time from the date of randomization in the study to the date when the first subsequent anti-tumor treatment starts

    Time frame: Approximately 36 months since the first subject enrolled

  3. PFS and OS assessed by BICR in patients with HRD (homologous recombination defects)

    positive patient population (including gBRCA-positive patients).

    Time frame: Approximately 36 months since the first subject enrolled

07

Study locations

31 sites
  • Anhui Provincal Hospital
    Hefei, Anhui, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • The first affiliated hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Guizhou Cancer hospital
    Guiyang, Guizhou, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Zhongnan hospital of wuhan university
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Xiangya Hospital Central South Hospital
    Changsha, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • second hospital of Shanxi medical university
    Taiyuan, Shanxi, China
  • West China second university hospital
    Chengdu, Sichuan, China
  • Tianjin Central Hospital of Gynecology Obstetrics
    Tianjin, Tianjin, China
  • Affiliate Cancer Hospital Xinjiang Medical University
    Urumqi, Xinjiang, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
  • Woman's hospital School of medicine Zhejiang University
    Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
  • the First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • Beijing Cancer Hospital
    Beijing, China
  • Cancer Hospital of Chinese Academy of Medical Sciences
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University People's hospital
    Beijing, China
  • Fudan University Shanghai Cancer Center
    Shanghai, China
  • Tianjin Tumour Hospital
    Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Jan 2022, 42 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 42 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2018
First posted
Oct 17, 2018
StartActual
Jun 30, 2018
Primary completionEst.
Jan 29, 2022
CompletionEst.
Dec 30, 2023
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03709316
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Jun 30, 2018
Primary completion
Jan 29, 2022 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Jun 2, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion